Cytokinetics, Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CYTK Nasdaq 8731 https://cytokinetics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cytokinetics, Inc.

EVP Research & Development Fady Malik Sells 2,500 Shares of Cytokinetics Inc - Sep 15th, 2023 5:05 am
Insider Sell: Cytokinetics Inc's President & CEO Robert Blum Sells 12,500 Shares - Sep 14th, 2023 5:02 am
10 Biotech Stocks with Biggest Upside - Sep 9th, 2023 7:59 pm
The 3 Best Mid-Cap Stocks to Buy Now: September 2023 - Sep 7th, 2023 8:29 pm
Cytokinetics to Participate in Upcoming Investor Conferences - Sep 7th, 2023 8:00 pm
Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy - Sep 6th, 2023 11:30 am
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 1st, 2023 8:00 pm
15 Worst Performing Biotech Stocks in 2023 - Aug 8th, 2023 10:20 am
Cytokinetics (CYTK) Reports Q2 Loss, Misses Revenue Estimates - Aug 3rd, 2023 9:15 pm
Cytokinetics Reports Second Quarter 2023 Financial Results - Aug 3rd, 2023 8:00 pm
Cytokinetics to Announce Second Quarter Results on August 3, 2023 - Jul 27th, 2023 8:00 pm
Cytokinetics' (NASDAQ:CYTK) investors will be pleased with their enviable 361% return over the last five years - Jul 27th, 2023 1:06 pm
Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy - Jun 20th, 2023 11:30 am
Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress - May 20th, 2023 2:30 pm
Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2023 Congress - May 15th, 2023 8:00 pm
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586 - May 11th, 2023 11:30 am
Cytokinetics to Participate in the JMP Securities Life Sciences Conference - May 8th, 2023 8:00 pm
Analysts' Revenue Estimates For Cytokinetics, Incorporated (NASDAQ:CYTK) Are Surging Higher - May 7th, 2023 12:09 pm
Q1 2023 Cytokinetics Inc Earnings Call - May 5th, 2023 2:14 pm
Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates - May 4th, 2023 9:15 pm